The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients

Liver International

Volumn 31, Issue 1, 2011, Pages 66-74

  Fattovich, Giovanna ^a,b   Covolo, Loredana ^c   Pasino, Michela ^a   Perini, Eleonora ^c   Rossi, Luigi ^d   Brocco, Giorgio ^d   Guido, Maria ^e   Cristofori, Chiara ^a   Belotti, Caterina ^c   Puoti, Massimo ^c   Gaeta, Giovanni Battista ^f   Santantonio, Teresa ^g   Raimondo, Giovanni ^h   Bruno, Raffaele ⁱ   Minola, Eliseo ^j   Negro, Francesco ^b   Donato, Francesco ^c  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF BRESCIA   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f SECOND UNIVERSITY OF NAPLES   (Italy)

^g UNIVERSITY OF FOGGIA   (Italy)

^h UNIVERSITY OF MESSINA   (Italy)

ⁱ UNIVERSITY OF PAVIA   (Italy)

^j OSPEDALI RIUNITI   (Italy)

more..

Author keywords

Hepatitis C virus genotype; Homeostasis model assessment of insulin resistance; Metabolic syndrome; Rapid virological response; Sustained virological response; Treatment na ve patients

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CAUCASIAN; DISEASE MODEL; FEMALE; GENOTYPE; HEPATITIS C; HOMEOSTASIS MODEL ASSESSMENT OF THE INSULIN RESISTANCE; HUMAN; INSULIN RESISTANCE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HEALTH STATUS INDICATORS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; INTERFERON ALFA-2A; INTERFERON ALFA-2B; ITALY; LOGISTIC MODELS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RIBAVIRIN; RISK ASSESSMENT; RISK FACTORS; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 78650155207     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02343.x     Document Type: Article

References (34)

1. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36 (Suppl. 1): S35-46.
2. Harrison SA. Insulin resistance among patients with chronic hepatitis C: etiology and impact on treatment. Clin Gastroenterol Hepatol 2008; 6: 864-76.
3. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol 2008; 49: 831-44.
4. Hui JM, Sud A, Farrell GC, Bandara P, et al. Insulin resistance is associated with chronic hepatitis C and virus fibrosis progression. Gastroenterology 2003; 125: 1695-704.
5. Sheikh MY, Choi J, Qadri I, et al. Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology 2008; 47: 2127-33.
6. Vanni E, Abate ML, Gentilcore E, et al. Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology 2009; 50: 697-706.
7. Milner KL, Van Der Poorten D, Trenell M, et al. Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology 2010; 138: 932-41.
8. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who respond less well ? Ann Intern Med 2004; 140: 370-81.
9. O'Brien TR. Interferon-alfa, interferon-λ and hepatitis C. Nat Genet 2009; 41: 1048-50.
10. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterfeon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-41.
11. Poustchi H, Negro F, Hui J, et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008; 48: 28-34.
12. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40kd)/ribavirin therapy. Hepatology 2006; 43: 954-60.
13. Yu ML, Dai CY, Huang JF, et al. Rapid virologic response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47: 1884-93.
14. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
15. Guidelines Committee. European society of hypertension-European society of cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.
16. Expert panel on detection evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA 2001; 285: 2486-97.
17. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degree of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 57-63.
18. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 289-93.
19. D'Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatiits C and in the response to antiviral therapy. Am J Gastroenterol 2005; 100: 1509-15.
20. Jian Wu Y, Shu Chen L, Gui-Qiang W. Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C. Liver Int 2006; 26: 166-72.
21. Chu CJ, Lee SD, Hung TH, et al. Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon α-2b plus ribavirin. Aliment Pharmacol Ther 2008; 29: 46-54.
22. Dai CY, Huang JF, Hsieh MY, et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 2009; 50: 712-8.
23. Cammà C, Bruno S, Di Marco V, et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 2006; 43: 64-71.
24. Lam KD, Bacchetti P, Abbasi F, et al. Comparison of surrogate and direct measurement of insulin resistance in chronic hepatitis C virus infection: impact of obesity and ethnicity. Hepatology 2010; 52: 38-46.
25. Miccoli R, Bianchi C, Odoguardi L, et al. Prevalence of the metabolic syndrome among Italian adults according to ATP III definition. Nutr Metab Cardiovasc Dis 2005; 15: 250-4.
26. Durante-Mangoni E, Zampino R, Portella G, et al. Correlates and prognostic value of the first-phase hepatitis C virus RNA kinetics during treatment. Clin Infect Dis 2009; 15: 498-506.
27. Grasso A, Malfatti F, De Leo P, et al. Insulin resistance predicts rapid virologic response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol 2009; 51: 984-90.
28. Bortoletto G, Scribano L, Realdon S, et al. Insulin resistance (IR) defined by the homeostasis model for assessment insulin resistance (HOMA-IR) index has a direct effect on early viral kinetics during pegylated-interferon therapy for chronic hepatits C. J Viral Hepatitis 2010; 17: 475-80.
29. Nasta P, Gatti F, Puoti M, et al. Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a. AIDS 2008; 22: 857-61.
30. Elgouhari HM, Cesario KB, Lopez R, et al. Pioglitazone improves early virologic kinetic response to PEG IFN/RBV combination therapy in hepatitis C genotype 1 naïve patients. Hepatology 2008; 48: 383A.
31. Conjeevaram H, Burant CF, McKenna B, et al. A randomized, double-blind, placebo controlled study of PPAR-gamma agonist pioglitazone given in combination with peginterferon and ribavirin in patients with genotype-1 chronic hepatitis C. Hepatology 2008; 48: 384A.
32. Overbeck K, Gennè D, Golay A, et al. Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin. J Hepatol 2008; 49: 295-98.
33. Vierling JM, Hamzeh FM, Lentz EL, et al. Virologic and metabolic responses in chronic hepatitis C (CHC) patients with insulin resistance (IR) treated with pioglitazone and peginterferon alfa-2a plus ribavirin. Hepatology 2009; 50: 1028A.
34. Romero-Gòmez M, Diago M, Andrade RJ, et al. Treatment of insulin resistance with metformin in naive genotype 1 chronic hepatitis patients receivign peginterferon alfa-2a plus ribavirin. Hepatology 2009; 50: 1702-8.